scientific presentations

MGTA-145, in Combination with Plerixafor, Rapidly Mobilizes Large Numbers of HSCs in Humans That Can Be Gene Edited with CRISPR/Cas9 and Mediate Superior Engraftment to Standard-of-Care (Abstract #123)

MGTA-145/Plerixafor-Mediated HSC Mobilization Allows for Efficient In Vivo HSC Transduction and Stable Gene Marking in Murine Peripheral Blood Cells (Abstract #810)

Phase 1 Clinical Study of MGTA-145 in Combination with Plerixafor Shows Rapid Single-Day Mobilization and Collection of CD34+ HSCs without G-CSF (Abstract #73)

Rapid and Robust Mobilization of CD34 + HSCs without G-CSF Following Administration of MGTA-145 Alone or in Combination with Plerixafor (Abstract #1961)

 

A Single Dose of CD117 Antibody Drug Conjugate Enables Hematopoietic Stem Cell Based Gene Therapy in Nonhuman Primates (Abstract #5)

A Non-Genotoxic Anti-CD117 Antibody Drug Conjugate (ADC) Designed for Patient Conditioning Prior to Stem Cell Transplant and HSC-Based Gene Therapy Has a Broad Therapeutic Window Across Species (Abstract #44)

A Single Dose of CD117 Antibody Drug Conjugate Enables Hematopoietic Stem Cell Based Gene Therapy in Nonhuman Primates (Abstract #610)

A Novel Targeted Approach to Achieve Immune System Reset: A Single Dose of Magenta CD45-Targeted Antibody Drug Conjugate Enables Autologous HSCT and Ameliorates Disease in Murine Models of Autoimmune Disease (Abstract #3208)

Administration of a CD45 Antibody Drug Conjugate As a Novel, Targeted Approach to Achieve Immune System Reset: A Single Dose of CD45-targeted ADC Safely Conditions for Autologous Transplant and Ameliorates Disease in Multiple Models of Autoimmune Disease (Abstract #120)

High Dose Hematopoietic Stem Cell Therapies, like MGTA-456, Enable Complete Neural, Peripheral, and Skeletal Disease Cross-Correction Through Rapid and Robust Engraftment (Abstract #248)

MGTA-456 Cell Therapy in Inherited Metabolic Diseases (IMD) Yields Rapid and Durable LongTerm Improvement of Disease-Specific Outcomes in a Phase 2 Trial (Abstract #20)

High Dose Hematopoietic Stem Cell Transplantation Leads to Rapid Neural and Peripheral Disease Cross-Correction via Robust Hematopoietic and Microglia Recovery

MGTA-456, An Aryl Hydrocarbon Receptor Antagonist Based Expansion of CD34+ Hematopoietic Stem Cells, Permits Selection of Better HLA Matched Cord Units and Promotes Faster Neutrophil Recovery and Uniform Engraftment With Potentially Less Acute Graft-vs-Host-Disease (Abstract #804)

Expansion with E478 Significantly Increases the Rate of CRISPR-Mediated Homology Directed Repair (HDR) and Improves Engraftment of Human Hematopoietic Stem Cells (Abstract #10)